Methylene Blue Reversal of Ifosfamide-Related Encephalopathy [1]

Journal of Pediatric Hematology/Oncology

Volumn 26, Issue 2, 2004, Pages 116-

  Raj, Ashok B ^a   Bertolone, Salvatore J ^a   Jaffe, Norman ^b  

^a University of Louisville School of Medicine   (United States)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; CYTOCHROME P450; ETOPOSIDE; IFOSFAMIDE; MESNA; METHYLENE BLUE;

AMNESIA; BRAIN DISEASE; CASE REPORT; COLOSTOMY; COMA; COMPUTER ASSISTED TOMOGRAPHY; DISORIENTATION; DRUG METABOLISM; ELECTROENCEPHALOGRAM; HUMAN; ILEOSTOMY; INFUSION; KIDNEY FAILURE; LETTER; MALE; NEUROTOXICITY; NUCLEAR MAGNETIC RESONANCE IMAGING; OSTEOSARCOMA; PELVIS EXENTERATION; PRIORITY JOURNAL; SCHOOL CHILD; SOMNOLENCE; SYMPTOMATOLOGY;

EID: 0442293664     PISSN: 10774114     EISSN: None     Source Type: Journal    
DOI: 10.1097/00043426-200402000-00010     Document Type: Letter

References (5)

1. Pelgrims J, De Vos F, Van den Brande J, et al. Methylene blue in the treatment and prevention of ifosfamide-induced encephalopathy: report of 12 cases and a review of the literature. Br J Cancer. 2000;82:291-294.
2. Aeschlimann C, Kupfer A, Schefer H, Cemy T. Comparative pharmacokinetics of oral and intravenous ifosfamide/mesna/methylene blue therapy. Drug Metab Dispos. 1998;26:883-890.
3. Kupfer A, Aeschlimann C, Cerny T. Methylene blue and the neurotoxic mechanisms of ifosfamide encephalopathy. Eur J Clin Pharmacol. 1996;50:249-252.
4. Harpey JP, Charpentier C, Coude M. Methylene-blue for riboflavin-unresponsive glutaric-aciduria type II. Lancet. 1986;1:391.
5. Hrushesky WJ, Olshefski R, Wood P, et al. Modifying intracellular redox balance: an approach to improving therapeutic index. Lancet. 1985;1:565-567.